Allspring Global Investments Holdings LLC Acquires Shares of 39,059 Caribou Biosciences, Inc. (NASDAQ:CRBU)

Allspring Global Investments Holdings LLC purchased a new stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 39,059 shares of the company’s stock, valued at approximately $224,000.

Several other large investors have also recently bought and sold shares of CRBU. Avidity Partners Management LP grew its holdings in shares of Caribou Biosciences by 119.3% in the 3rd quarter. Avidity Partners Management LP now owns 6,050,212 shares of the company’s stock worth $28,920,000 after acquiring an additional 3,291,612 shares during the period. Vanguard Group Inc. raised its position in Caribou Biosciences by 49.3% during the third quarter. Vanguard Group Inc. now owns 3,822,151 shares of the company’s stock worth $18,270,000 after acquiring an additional 1,261,920 shares during the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in shares of Caribou Biosciences in the third quarter valued at about $16,730,000. Assenagon Asset Management S.A. grew its position in shares of Caribou Biosciences by 247.5% in the third quarter. Assenagon Asset Management S.A. now owns 2,648,582 shares of the company’s stock valued at $12,660,000 after purchasing an additional 1,886,484 shares during the last quarter. Finally, Alkeon Capital Management LLC increased its stake in shares of Caribou Biosciences by 21.2% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,644,863 shares of the company’s stock worth $7,862,000 after purchasing an additional 287,800 shares in the last quarter. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Stock Performance

Shares of CRBU opened at $3.71 on Friday. Caribou Biosciences, Inc. has a 1 year low of $3.44 and a 1 year high of $8.59. The company’s 50 day simple moving average is $5.52 and its 200 day simple moving average is $5.42. The company has a market capitalization of $335.07 million, a price-to-earnings ratio of -2.56 and a beta of 2.47.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings results on Monday, March 11th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.17). The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.17 million. Caribou Biosciences had a negative return on equity of 31.06% and a negative net margin of 296.05%. Equities analysts expect that Caribou Biosciences, Inc. will post -1.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright raised their price target on Caribou Biosciences from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.